News

FDA Clears Frontera’s FT-002 for Phase II Clinical Trials in the U.S.

By Frontera News | September 22, 2024

Boston, MA, September 23, 2024 – Frontera is excited to announce that its gene therapy product, FT-002, has been cleared by the U.S. Food and Drug Administration (FDA) for Phase II clinical trials in the U.S. This approval marks a major milestone, as FT-002 becomes the first recombinant adeno-associated virus (rAAV) gene therapy to receive […]

Read More

2024 Highlights of the 5th Gene Therapy for Ophthalmic Disorders Summit: Frontera’s AAV Capsids for Suprachoroidal Delivery

By Frontera News | September 13, 2024

Sep 10-12, 2024— the 5th Annual Gene Therapy for Ophthalmic Disorders Summit was held in Boston, USA. Dr. Zhong-Dong Shi, Executive Director, head of R&D, Frontera Therapeutics, was invited to participate in discussion on “Optimizing Capsid Design & Vector Engineering for Ophthalmic Gene Therapy” and gave a keynote address on “Novel AAV Capsids for Suprachoroidal Delivery”. […]

Read More

Frontera Therapeutics’s Quality Control for rAAV Gene Therapy Products Presented at the 23rd China Biological Products Annual Conference 2024

By Frontera News | May 19, 2024

May 16-18, 2024— the 23rd China Biological Products Annual Conference was held in Guangzhou, China. Dr. Li Aiqun, Director of QC, Frontera Therapeutics, was invited to participate in the symposium of “Immune Cells, Stem Cells and Gene Therapy” and focused on “Quality Control of rAAV Gene Therapy Products: Challenges of Next Generation Sequencing and Residual DNA […]

Read More

Frontera Therapeutics Unveils Preliminary Clinical Results for FT-002 Injection at Retinal Cell and Gene Therapy Innovation Summit 2024

By Frontera News | May 6, 2024

May 6, 2024–Frontera Therapeutics is pleased to announce significant advancements in our clinical study of FT-002, presented at Retinal Cell and Gene Therapy Innovation Summitin the United States on May 3, 2024. Professor Sui Ruifang, from Peking Union Medical College Hospital, was invited to present the clinical results, titled “Preliminary safety and efficacy of an […]

Read More

Frontera Therapeutics to Showcase at the International Conferences in May 2024

By Frontera News | April 24, 2024

Boston, MA, USA – April 22, 2024. Frontera Therapeutics is excited to announce its participation in several esteemed conferences in May 2024, where it will present groundbreaking research across multiple therapeutic areas, including ophthalmology, blood and cardiovascular diseases.  The conferences are the 2024 Retinal Cell and Gene Therapy Innovation Summit, the 2024 American Ophthalmology Congress, […]

Read More

Frontera’s “Innovative Solutions of rAAV Purification Process” Unveiled at the 7th Gene Therapy for Rare Disorder 2024

By Frontera News | April 1, 2024

Boston, MA, USA – April 1, 2024. The 7th Gene Therapy for Rare Disorder 2024 took place in Boston, MA from March 26 to 29, 2024. Dr. Hongxiang Lu, Senior Vice President of Frontera Therapeutics, was invited to participate in the panel discussion on “Gene Drug Manufacturing” and gave a keynote presentation on “Case Studies […]

Read More

Frontera’s Study Report on ” Case Studies of Resolving rAAV Aggregation & Removing Empty Vectors ” will be presented in Gene Therapy for Rare Disorders 2024

By Frontera News | March 18, 2024

Boston, USA – March 18, 2024 – Frontera Therapeutics, a leading biotechnology company committed to advancing gene therapy drugs to address unmet medical needs worldwide, is delighted to announce its participation in the upcoming 7th Gene Therapy for Rare Disorders 2024 Conference in Boston, USA. Dr. Robert Lu, Senior Vice President of Frontera, has been […]

Read More

Frontera Therapeutics’ FT-002 Achieves Orphan Drug Designation from the U.S. FDA for Inherited Retinal Dystrophies

By Frontera News | January 23, 2024

BEDFORD, Mass., and Suzhou, China, January 23, 2024 — Frontera Therapeutics announces that its pioneering AAV gene therapy product, FT-002, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of Inherited Retinal Dystrophies (IRD) caused by RPGR gene variants. About Orphan Drug Designation Orphan Drug Designation, granted […]

Read More

Preliminary Clinical Study Results of Frontera Therapeutics FT-002 Injection Presented at APVRS Congress

By Frontera News | December 10, 2023

Hongkong, China, Decemeber 8th, 2023 – Preliminary clinical study results of FT-002, an AAV gene therapy treatment of Frontera Therapeutics, a potential first in class therapy for the treatment of XLRP, were reported at the 16th Asia-Pacific Vitreo-Retina Society, APVRS, 2023). Professor Sui Ruifang from Peking Union Medical College Hospital was invited to participate in […]

Read More

Frontera Therapeutics Initiates Phase II Clinical Trial for FT-001 in Hereditary Retinopathy Treatment

By Frontera News | December 5, 2023

Beijing, China, Decemeber 3rd, 2023 – Frontera Therapeutics (Suzhou) Co., Ltd. (hereinafter referred to as Frontera Therapeutics) convened a meeting in Beijing on December 3 to conclude the Phase I clinical study of FT-001, and initiate the Phase II clinical study. The meeting was attended by esteemed clinical experts, including Professor Sui Ruifang, Professor Yu […]

Read More